LIDDS AB (publ) (STO:LIDDS)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.0850
0.00 (0.00%)
Aug 26, 2025, 3:00 PM CET
Market Cap11.60M
Revenue (ttm)9.00K
Net Income (ttm)-7.24M
Shares Out136.46M
EPS (ttm)-0.05
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume15,372
Average Volume132,482
Open0.0850
Previous Close0.0850
Day's Range0.0850 - 0.0850
52-Week Range0.0304 - 0.2300
Beta0.26
RSI59.06
Earnings DateAug 28, 2025

About LIDDS AB

LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, whic... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 6
Stock Exchange Nasdaq Stockholm
Ticker Symbol LIDDS
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.